Entera Bio Ltd. ROA

ROA of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROA growth rates and interactive chart. Return on Assets (ROA) is an indicator of how well a company utilizes its assets, by determining how profitable a company is relative to its total assets. A company with $1 million in net income and $10 million in average assets will have a 10% ROA.

Highlights and Quick Summary

  • Annual ROA for 2019 was -71.86% (a -7.18% decrease from previous year)
  • Annual ROA for 2018 was -77.42% (a -Infinity% decrease from previous year)
  • Twelve month ROA ending June 29, 2020 was -122.28% (a 51.67% increase compared to previous quarter)
  • Twelve month trailing ROA decreased by -55.23% year-over-year
Trailing ROA for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-122.28% -80.62% -71.86% -273.11%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROA of Entera Bio Ltd.

Most recent ROAof ENTX including historical data for past 10 years.

Interactive Chart of ROA of Entera Bio Ltd.

Entera Bio Ltd. ROA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -71.86%
2018 -77.42%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.